KalVista Pharmaceuticals to Present at Upcoming Investor Conferences

Rhea-AI Summary

KalVista Pharmaceuticals, a clinical-stage pharmaceutical company focusing on oral, small molecule protease inhibitors, announced participation in two upcoming investor conferences. The management will join a virtual fireside chat at the Stifel 2024 Tailoring Genes: Genetic Medicines Forum on May 28, 2024, at 12:50 p.m. ET, and the Jefferies Global Healthcare Conference in New York on June 5, 2024, at 3:00 p.m. ET. The presentations will be webcasted live, with an audio archive available on the company's website for 30 days post-event.

Positive

• Participation in high-profile investor conferences could boost visibility and investor interest.
• Hosting a virtual fireside chat provides accessibility to a broader audience.

Negative

• The announcement lacks concrete updates on financial or clinical milestones, which could be seen as a missed opportunity to boost investor confidence.
• No new data or significant business developments were disclosed, which might not favorably impact the stock price.

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced its management will participate in fireside chats at the following upcoming conferences:

• Stifel 2024 Tailoring Genes: Genetic Medicines Forum – Virtual fireside chat on Tuesday, May 28, 2024 at 12:50 p.m. ET.

• Jefferies Global Healthcare Conference in New York on Wednesday, June 5, 2024 at 3:00 p.m. ET.

A live webcast of the presentation will be available on the Company’s website at www.kalvista.com. An audio archive will be available on KalVista’s website for 30 days following the presentations.

About KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals, Inc. is a global pharmaceutical company focused on the development and delivery of oral medicines for diseases with significant unmet need. KalVista disclosed positive phase 3 data for the KONFIDENT trial for its oral, on-demand therapy sebetralstat in February 2024. The Company anticipates submitting a new drug application to the U.S. Food and Drug Administration (FDA) for sebetralstat in June 2024 and expects to file for approval in the UK, Europe and Japan later in 2024.

For more information about KalVista, please visit www.kalvista.com.

Forward-Looking Statements

This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. These statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from what we expect. Examples of forward-looking statements include, among others, timing or outcomes of communications with the FDA or other international regulatory agencies, our expectations about safety and efficacy of our product candidates, our ability to obtain regulatory approvals for sebetralstat and other candidates in development within our expected timelines or at all, our success in engaging with potential commercial partners, the success of any efforts to commercialize sebetralstat, the ability of sebetralstat and other candidates in development to treat HAE or other diseases, our ability to commence pediatric trials of sebetralstat and develop an ODT formulation, the future progress and potential success of our oral Factor XIIa program, our ability to reduce spending on discovery and preclinical activities, and our expectation to become cash flow positive. Further information on potential risk factors that could affect our business and financial results are detailed in our filings with the Securities and Exchange Commission, including in our annual report on Form 10-K for the year ended April 30, 2023, our quarterly reports on Form 10-Q, and our other reports that we may make from time to time with the Securities and Exchange Commission. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240521674499/en/

KalVista Pharmaceuticals, Inc.

Jarrod Aldom

Vice President, Corporate Communications

(201) 705-0254

jarrod.aldom@kalvista.com

Ryan Baker

Head, Investor Relations

(617) 771-5001

ryan.baker@kalvista.com

Source: KalVista Pharmaceuticals, Inc.

FAQ

What is the date and time for KalVista Pharmaceuticals' presentation at the Stifel 2024 Tailoring Genes: Genetic Medicines Forum?

KalVista will present a virtual fireside chat on May 28, 2024, at 12:50 p.m. ET.

When is KalVista Pharmaceuticals presenting at the Jefferies Global Healthcare Conference?

KalVista will present on June 5, 2024, at 3:00 p.m. ET.

Where can I watch the live webcast of KalVista Pharmaceuticals' presentations?

The live webcast will be available on KalVista's website at www.kalvista.com.

How long will the audio archive of KalVista Pharmaceuticals' presentations be available?

The audio archive will be available on the company's website for 30 days following the presentations.